There were no significant differences between YOD and LOD in terms of numbers of patients with eligible subtypes (i.e. a diagnosis of Alzheimer's disease, mixed dementia, dementia with Lewy bodies or Parkinson's disease dementia) prescribed cholinesterase inhibitors and/or memantine (data not shown). This evidence concerns the gene BCHE and Lewy body dementia.